Literature DB >> 20430581

Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.

Julia F Simard1, Matthew L Stoll, Nancy A Shadick, Elizabeth W Karlson, Daniel H Solomon.   

Abstract

OBJECTIVE: We evaluated and compared the validity of patients' and rheumatologists' reports of infection with those confirmed by medical record review. STUDY DESIGN AND
SETTING: Reports of infections in 961 patients with rheumatoid arthritis from the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) were included over a 2-year period. BRASS is a longitudinal prospective cohort that collects detailed questionnaire data from patients semiannually and their treating rheumatologists every year.
RESULTS: Rheumatologist report of infection was more likely to be confirmed by medical record review than patient self-report (57.1% vs. 34.3% for definite or possible infections). Confirmation rates varied based on whether the participant received her primary care from the same network of health care providers. For participants with primary care "out of network," between 7.0% and 23.1% of patient or rheumatologist reports were confirmed by medical record review vs. between 16.1% and 41.7% for those with primary care "in network."
CONCLUSION: The present study shows that relying strictly on patient or rheumatologist report of infection for a confirmed endpoint is not ideal but useful in case finding. The confirmation rate is affected by a number of factors including severity and definition of the infection and limited by data availability.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430581      PMCID: PMC2954263          DOI: 10.1016/j.jclinepi.2010.01.014

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  8 in total

1.  Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.

Authors:  J R Curtis; C Martin; K G Saag; N M Patkar; J Kramer; D Shatin; J Allison; M M Braun
Journal:  Arthritis Rheum       Date:  2007-03-15

2.  Post-marketing strategies for medicines.

Authors:  A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  2007-11-28       Impact factor: 6.875

3.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.

Authors:  Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2006-12-18       Impact factor: 6.437

4.  Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.

Authors:  Johan Askling; C Michael Fored; Lena Brandt; Eva Baecklund; Lennart Bertilsson; Nils Feltelius; Lars Cöster; Pierre Geborek; Lennart T Jacobsson; Staffan Lindblad; Jörgen Lysholm; Solbritt Rantapää-Dahlqvist; Tore Saxne; Ronald F van Vollenhoven; Lars Klareskog
Journal:  Ann Rheum Dis       Date:  2007-01-29       Impact factor: 19.103

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

6.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K Watson; M Lunt; K L Hyrich; A J Silman; D P M Symmons
Journal:  Arthritis Rheum       Date:  2006-08

7.  Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate.

Authors:  M J van der Veen; A van der Heide; A A Kruize; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1994-04       Impact factor: 19.103

Review 8.  Infections during low-dose methotrexate treatment in rheumatoid arthritis.

Authors:  A M Boerbooms; P J Kerstens; J W van Loenhout; J Mulder; L B van de Putte
Journal:  Semin Arthritis Rheum       Date:  1995-06       Impact factor: 5.532

  8 in total
  2 in total

1.  TNF-α Antagonist and Infection in Rheumatoid Arthritis.

Authors:  Julia F Simard; Murray A Mittleman; Nancy A Shadick; Elizabeth W Karlson
Journal:  Open J Rheumatol Autoimmune Dis       Date:  2012-05

2.  A transient peak of infections during onset of rheumatoid arthritis: a 10-year prospective cohort study.

Authors:  Marina I Arleevskaya; Aida G Gabdoulkhakova; Yulia V Filina; Regina R Miftakhova; Anders Bredberg; Anatoly P Tsybulkin
Journal:  BMJ Open       Date:  2014-09-01       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.